مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

260
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

107
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

RESISTANCE TO HER2-TARGETED THERAPY

Pages

  1-9

Abstract

 Production and approval of TRASTUZUMAB (HerceptinÒ) for the treatment of metastatic BREAST CANCER (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, TRASTUZUMAB failed to appreciate the initial attraction due to development of RESISTANCE to the drug. Majority of patients who benefit from the drug acquire RESISTANCE to it and experience tumor recurrence within 1 year. Several molecular and cellular mechanisms underlying the RESISTANCE to TRASTUZUMAB have been proposed. In this review, first, we provide a brief history leading to production of TRASTUZUMAB. Also we consider the cellular and molecular antitumor effects of TRASTUZUMAB and then, we discuss the mechanisms underlying TRASTUZUMAB RESISTANCE in four levels.

Multimedia

  • No record.

    • Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    VALADAN, REZA, RAFIEI, ALIREZA, TEHRANI, MOHSEN, & NEJATOLLAHI, FOROUGH. (2013). RESISTANCE TO HER2-TARGETED THERAPY. RESEARCH IN MOLECULAR MEDICINE, 1(1), 1-9. SID. https://sid.ir/paper/336949/en

    Vancouver: Copy

    VALADAN REZA, RAFIEI ALIREZA, TEHRANI MOHSEN, NEJATOLLAHI FOROUGH. RESISTANCE TO HER2-TARGETED THERAPY. RESEARCH IN MOLECULAR MEDICINE[Internet]. 2013;1(1):1-9. Available from: https://sid.ir/paper/336949/en

    IEEE: Copy

    REZA VALADAN, ALIREZA RAFIEI, MOHSEN TEHRANI, and FOROUGH NEJATOLLAHI, “RESISTANCE TO HER2-TARGETED THERAPY,” RESEARCH IN MOLECULAR MEDICINE, vol. 1, no. 1, pp. 1–9, 2013, [Online]. Available: https://sid.ir/paper/336949/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button